Janux Therapeutics Appoints Janeen Doyle as Chief Corporate and Business Development Officer
'Janeen's unique blend of corporate development, strategic execution, and clinical insight makes her an ideal leader to help drive the next phase of growth at Janux,' said David Campbell, Ph.D., President and CEO of Janux. 'Her proven track record of building value through transformational partnerships and her ability to integrate business and science will be instrumental as we continue advancing our pipeline of tumor-activated therapeutics.'
'I'm thrilled to join Janux at such an exciting time as the company expands its clinical programs and continues to advance its pipeline,' said Ms. Doyle. 'The company's innovative TRACTr and TRACIr platforms and its commitment to delivering safer, more effective therapies to cancer patients present tremendous opportunities. I look forward to working with the team to shape and execute the company's corporate and business development strategy.'
Ms. Doyle brings more than 24 years of broad and strategic experience spanning large pharmaceutical companies, mid-sized biotech, and high-growth venture-backed enterprises. She joins Janux from Flagship Pioneering, a life sciences-focused venture capital firm, where she served as a Senior Partner and Senior Vice President of Corporate Partnerships and Program Development. At Flagship, she was responsible for strategy and execution of collaborations between Flagship's portfolio companies and global pharmaceutical and technology partners.
Prior to Flagship, Ms. Doyle spent over 15 years at Bristol Myers Squibb and Celgene in a breadth of cross-functional positions of increasing responsibility, starting in areas of medical affairs and program leadership, and most recently serving as Senior Vice President of Strategy & Business Development. In that role, she oversaw a portfolio of 300+ strategic collaborations and a broad equity investing portfolio, including serving as a board observer across investments. Her leadership encompassed partnerships from discovery through commercialization across multiple therapeutic areas. Previous to this, she held roles in clinical science and operations.
Janux's TRACTr and TRACIr Pipeline
Janux's first clinical candidate, JANX007, is a TRACTr that targets prostate-specific membrane antigen (PSMA) and is being investigated in a Phase 1 clinical trial in adult patients with metastatic castration-resistant prostate cancer (mCRPC). Janux's second clinical candidate, JANX008, is a TRACTr that targets epidermal growth factor receptor (EGFR) and is being studied in a Phase 1 clinical trial for the treatment of multiple solid cancers including colorectal carcinoma, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma and triple-negative breast cancer. We are also generating a number of additional TRACTr and TRACIr programs for potential future development, some of which are at development candidate stage or later. We are currently assessing priorities in our preclinical pipeline.
About Janux Therapeutics
Janux is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Janux's proprietary technology enabled the development of two distinct bispecific platforms: TRACTr and TRACIr. The goal of both platforms is to provide cancer patients with safe and effective therapeutics that direct and guide their immune system to eradicate tumors while minimizing safety concerns. Janux is currently developing a broad pipeline of TRACTr and TRACIr therapeutics directed at several targets to treat solid tumors. Janux has two TRACTr therapeutic candidates in clinical trials, the first targeting PSMA is in development for prostate cancer, and the second targeting EGFR is being developed for colorectal carcinoma, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma and triple-negative breast cancer. For more information, please visit www.januxrx.com and follow us on LinkedIn.
Forward-Looking Statements
This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, Janux's ability to bring new treatments to cancer patients in need, expectations regarding the timing, scope and results of Janux's development activities, including its ongoing and planned preclinical studies and clinical trials, the timing of and plans for regulatory filings, the potential benefits of Janux's product candidates and platform technologies, and expectations regarding the use of Janux's platform technologies to generate novel product candidates and the strength of Janux's balance sheet and the adequacy of cash on hand. Factors that may cause actual results to differ materially include the risk that compounds that appear promising in early research do not demonstrate safety and/or efficacy in later preclinical studies or clinical trials, the risk that Janux may not obtain approval to market its product candidates, uncertainties associated with performing clinical trials, regulatory filings and applications, risks associated with reliance on third parties to successfully conduct clinical trials, the risks associated with reliance on outside financing to meet capital requirements, and other risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. You are urged to consider statements that include the words 'may,' 'will,' 'would,' 'could,' 'should,' 'believes,' 'estimates,' 'projects,' 'promise,' 'potential,' 'expects,' 'plans,' 'anticipates,' 'intends,' 'continues,' 'designed,' 'goal,' or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties Janux faces, please refer to Janux's periodic and other filings with the Securities and Exchange Commission, which are available at www.sec.gov. Such forward-looking statements are current only as of the date they are made, and Janux assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
28 minutes ago
- Yahoo
US Equity Indexes Jump After July Inflation Boosts Fed Rate-Cut Expectations
US equity indexes jumped in midday trading Tuesday, with the Nasdaq Composite and S&P 500 hitting al
Business Wire
29 minutes ago
- Business Wire
Ncontracts Named to Inc. 5000 for a Seventh Consecutive Year
BRENTWOOD, Tenn.--(BUSINESS WIRE)-- Ncontracts, the leading provider of integrated compliance, risk, and vendor management solutions to the financial services industry, today announced it has been ranked No. 3,068 on the 2025 Inc. 5000 list of the fastest-growing private companies in America. This marks the 7th consecutive year the company has earned a place on the prestigious list. This marks the 7th consecutive year the company has earned a place on the prestigious list. The Inc. 5000 recognizes independent businesses that have demonstrated exceptional revenue growth and innovation. Ncontracts' sustained presence on the list demonstrates Ncontracts' commitment to innovation and excellence in serving the evolving needs of financial institutions, mortgage companies, and registered investment advisors nationwide as they seek comprehensive, integrated solutions for their risk and compliance challenges. "This milestone reflects not just our growth, but our continued evolution as the industry's most trusted partner for integrated risk and compliance management,' said Michael Berman, founder and CEO of Ncontracts. 'As the risk landscape becomes increasingly complex, we remain committed to delivering innovative solutions that help our clients navigate these challenges with confidence." Today, Ncontracts serves more than 5,000 financial institutions, fintechs, mortgage companies, registered investment advisors, broker-dealers, trust companies, and other financial services organizations nationwide with solutions covering the full lifecycle of risk, compliance, and third-party risk management. The company's growth is driven by rising demand for integrated risk and compliance solutions, continued acquisitions in the governance, risk and compliance (GRC) space such as third-party risk management leader Venminder, and ongoing innovation, including the introduction of AI-powered tools. Ncontracts is a Preferred Service Provider (PSP) of The Independent Community Bankers of America (ICBA), a Premier Partner of the American Bankers Association's Partner Network, and endorsed by 11 state bank associations. Through a strategic agreement with America's Credit Unions, Ncomply, Ncontracts' flagship compliance management system, along with the company's complete portfolio of risk management solutions, will be promoted to help credit unions streamline operations and reduce costs. Financial organizations turn to Ncontracts to transform their enterprise risk and compliance management efforts. The platform's advanced tools simplify complex monitoring and reporting requirements while facilitating seamless risk communication throughout the organization. Through its knowledge-as-a-service (KaaS) approach, clients gain access to both sophisticated software and specialized expertise, creating a comprehensive solution that lightens compliance workloads and delivers the critical data needed for faster, more informed business decisions. This latest recognition builds on a strong foundation of workplace excellence awards that demonstrate the company's commitment to fostering an environment where both employees and the business can thrive. Earlier this year, the company was named a USA TODAY 2025 Top Workplace for the third year in a row and a Top Workplace by The Tennessean for a fifth consecutive year. About Ncontracts Ncontracts provides integrated risk management, compliance, and third-party risk management solutions to over 5,000 financial organizations including financial institutions, mortgage companies, registered investment advisors, and fintechs. Ncontracts solutions combine software with expert services to help financial organizations streamline risk and compliance management through an intuitive, cloud-based platform. Visit or follow the company on LinkedIn and X for more information.
Business Wire
29 minutes ago
- Business Wire
Spectrum Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights
LOS ANGELES--(BUSINESS WIRE)-- The DJS Law Group reminds investors of a class action lawsuit against Spectrum Pharmaceuticals, Inc. ('Spectrum' or 'the Company') (NASDAQ: SPPI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of SPPI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery. CLASS PERIOD: DEADLINE: September 24, 2025 CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Spectrum's Pinnacle Study of poziotinib for the treatment of lung cancer was less positive than it portrayed to investors. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. If you are a shareholder who suffered a loss, contact us to participate. NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of SPPI during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. There is no cost or obligation to you to participate in this case. WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results. Join the case to recover your losses. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
